Gland Pharma gets USFDA approval for Sugammadex Injection, Day 1 launch

Regulatory product approvalBusiness Updates View source PDF Explain this filing

GLAND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.4%Reaction day

₹2434.00

prior close

₹2485.00

announcement price

In-mkt

timing

Nifty Smallcap 250market+1.3%+3.1% vs market

Pharmaceuticals peers, median of 160sector+0.8%+3.7% vs sector

On the reaction day the stock moved 3.1 pts more than Nifty Smallcap 250 and 3.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+0.1

15m

+0.2

30m

+0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.4+1.3+3.1+0.8+3.7

Next day

+3.6+0.6+3.0-0.0+3.6

+2.9+1.0+1.9+0.1+2.9

+6.2+2.4+3.8+0.6+5.6

+6.3+2.6+3.8+1.0+5.3

+4.8+3.3+1.6+0.6+4.2

+6.1+3.5+2.6+1.5+4.6

15d

+16.6+2.8+13.8+0.3+16.3

+18.5+3.6+15.0+1.9+16.6

+22.6+0.0+22.6+3.3+19.3

+25.8-3.6+29.4-2.2+28.0

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Gland Pharma received USFDA approval for its generic Sugammadex Injection in two strengths (200 mg/2 mL and 500 mg/5 mL single-dose vials), a generic of Merck's BRIDION used to reverse muscle relaxation during surgery. The company launched the product on Day 1 through its marketing partner. The reference brand had US sales of about USD 1.6 billion in the 12 months ending April 2026, indicating a large market opportunity.

Likely market impact

Positive: opens access to a large billion-dollar US market for a new generic, with Day 1 launch expected to drive early revenue.